drugset / Trial / NCT05965570

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

NCT05965570

Phase 1 Completed 22 enrolled Insmed Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.

Timeline

Start
2023-07-28
Primary completion
2023-09-22
Completion
2023-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Brensocatib Small molecule Oral
Subject Clarithromycin Small molecule Oral

Indications

No indication recorded.